Welcome to our dedicated page for Galectin Therapeutics SEC filings (Ticker: GALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galectin Therapeutics Inc. (NASDAQ: GALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer, Galectin Therapeutics uses these filings to report on its financial condition, clinical development activities, governance, and capital structure.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of the company’s business, including its focus on galectin-targeted therapeutics and the belapectin program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension. Current reports on Form 8-K highlight material events such as clinical data disclosures, new or supplemental lines of credit, changes to compensation arrangements, and the posting of updated corporate presentations.
Proxy materials, including definitive proxy statements on Schedule 14A, describe items submitted to stockholders, such as director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. These documents also outline aspects of corporate governance, board structure, and equity compensation.
Through this page, users can also monitor filings that relate to financing arrangements, including convertible promissory notes and warrants, which may affect Galectin Therapeutics’ capital resources and potential dilution. Real-time updates from EDGAR are paired with AI-powered summaries that highlight key points in lengthy reports, helping readers quickly identify information on topics such as the NAVIGATE trial, belapectin’s regulatory status, and risk factor disclosures.
For those researching GALT, this filings archive offers a structured view of the company’s official disclosures, from financial reporting to governance decisions, with tools to make complex regulatory documents easier to understand.
Galectin Therapeutics director Kary Eldred received a new stock option grant. On January 16, 2026, Eldred was awarded options to purchase 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share. These options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and vest 100% on December 31, 2026, meaning they become fully exercisable on that date. The options expire on January 16, 2036 if not exercised. Following this grant, Eldred beneficially owns 60,000 derivative securities directly in the form of these stock options.
Galectin Therapeutics Inc. reported new equity awards for its President and CEO, Lewis Joel, who also serves as a director. On January 16, 2026, he was granted 84,000 stock options with an exercise price of $3.04 per share under the company’s 2019 Omnibus Equity Incentive Plan. The options vest in four equal installments of 25% on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
On the same date, Joel also received 120,000 Restricted Stock Units (RSUs), which vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement. Each vested RSU converts into one share of Galectin common stock.
Galectin Therapeutics Inc. Chief Financial Officer Jack W. Callicutt reported new equity awards from the company. On January 16, 2026, he received a stock option for 65,000 shares of common stock at an exercise price of $3.04 per share, expiring on January 16, 2036. The options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.
On the same date, he was also granted 100,000 Restricted Stock Units. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. All awards were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, and are reported as directly owned by the officer.
Galectin Therapeutics Inc. granted stock options to a board member. Director Harold H. Shlevin received stock options covering 60,000 shares of Galectin Therapeutics common stock on January 16, 2026. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan with an exercise price of $3.04 per share and expire on January 16, 2036. The options vest 100% on December 31, 2026, meaning Shlevin must remain eligible through that date before they become fully exercisable. Following this grant, he beneficially owns 60,000 derivative securities, held directly.
Galectin Therapeutics Inc. director Gilbert S. Omenn reported receiving a grant of derivative securities in the form of stock options. On January 16, 2026, he was awarded 60,000 stock options (right to buy) with a stated exercise price of $0 per share, all held in a direct ownership capacity. Following this grant, he beneficially owned 60,000 derivative securities linked to the company’s common stock. The options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and are scheduled to vest 100% on December 31, 2026, meaning they become fully exercisable on that date.
Galectin Therapeutics (GALT) director granted stock options
Galectin Therapeutics director Gilbert F. Amelio reported receiving stock options for 60,000 shares of the company’s common stock on January 16, 2026. The options have an exercise price of $3.04 per share and were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. According to the filing, the options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Amelio beneficially owns 60,000 stock options directly.
Galectin Therapeutics Inc. director Elissa J. Schwartz received a grant of stock options for 60,000 shares of common stock. The options were awarded on January 16, 2026 under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan with an exercise price of $3.04 per share and an expiration date of January 16, 2036.
The filing states that these options vest 100% on December 31, 2026, meaning they become fully exercisable on that date. Following this grant, Schwartz beneficially owns 60,000 derivative securities in the form of stock options, held directly.
Galectin Therapeutics director and 10% owner Richard E. Uihlein reported equity awards from the company. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share under the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. These options vest 100% on December 31, 2026.
On the same date, he was also issued 13,158 shares of common stock at $3.04 per share in lieu of a $40,000 cash retainer and meeting fees for 2026, with restrictions on these shares lapsing 25% at the end of each calendar quarter in 2026. Following these transactions, he directly held 10,332,676 common shares and 60,000 options, and indirectly 27,710 shares through the Ed Uihlein Family Foundation, where he shares voting and dispositive power but has no pecuniary interest.
Galectin Therapeutics Inc. President and CEO Joel Lewis, who also serves as a director, reported equity compensation activity involving the company’s common stock. On January 5, 2026, 56,332 shares of common stock were reported at a price of $3.88 per share, reflecting settlement of deferred stock units (DSUs) and related share withholding for taxes. Following the transaction, Lewis beneficially owned 776,260 shares directly, which represent shares underlying DSUs and common stock.
Under Lewis’s employment and Deferred Stock Unit Agreements, 80% of his compensation is paid in DSUs, with DSUs from the amended agreement settling in common stock, including a tranche on January 5, 2026. The filing also shows 2,000 shares held indirectly as custodian for a minor child under the Uniform Transfer to Minors Act, for which Lewis expressly disclaims beneficial ownership.
Galectin Therapeutics Inc. reported that Marc Rubin resigned from its Board of Directors effective January 10, 2026. The company states that his resignation is not due to any disagreement with Galectin on its operations, policies, or practices, indicating an orderly governance change rather than a dispute-driven departure.